- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
WASHINGTON — The pharmaceutical industry has sparred with President Trump for four years over drug pricing. Now it’s taking its biggest gamble yet: calling the president’s bluff. The most
brazen move came this week: Unlike most CEOs, who jump at the chance to visit the White House, pharmaceutical executives — newly empowered by their high-profile efforts to respond to the
coronavirus and fed up with President Trump’s repeated threats — responded to his latest invitation with open contempt. Trump insisted last week that his administration’s tough talk on drug
pricing had left drug makers clamoring to strike a deal with the administration and that CEOs would be at the White House next week to formally begin negotiations. In a rare show of
defiance, drug makers skipped the meeting, several outlets reported. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE
— PLUS DAILY INTELLIGENCE ON CAPITOL HILL AND THE LIFE SCIENCES INDUSTRY — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the
rest of this story subscribe to STAT+. Subscribe
